Melbourne Melanoma Project committed to improving the diagnosis and early detection of melanoma.

Frontline Nivolumab/Ipilimumab Combo Delivers Long-Term OS Advantage in Melanoma

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a sustained survival benefit compared with nivolumab or ipilimumab alone, according to 5-year follow-up results from the phase III CheckMate-067 trial presented at the 16th International Congress of the Society for Melanoma Research.1

Expert Weighs in on Targeted and Immunotherapy Combinations in Melanoma

Although multiple combinations of BRAF and MEK inhibitors have been approved by the FDA for the treatment of patients with melanoma, more trials are underway to identify regimens of targeted agents plus immunotherapies to better benefit this patient population, according to Ryan J. Sullivan, MD.

Expert Highlights Potential Markers of Nivolumab/Ipilimumab Response in Melanoma

Subgroup analyses from the phase III CheckMate-067 trial identified potential biomarkers in patients who achieved a complete response (CR) with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) but later progressed, according to Georgina V. Long, BSc, PhD, MBBS, FRACP.1

Cobimetinib/Vemurafenib OS Benefit Sustained at 5 Years in BRAF+ Melanoma

Combining the MEK inhibitor cobimetinib (Cotellic) with the BRAF inhibitor vemurafenib (Zelboraf) provides long-term clinical benefits for patients with BRAF V600–mutated metastatic melanoma.